Coverage & Payment
The consequences to patients with financial concerns might be significant. Genentech Rheumatology Access Solutions can help. We offer several options to help cover the cost of medicines for ACTEMRA patients who are uninsured, rendered uninsured by payer denial, underinsured or who have concerns about their co-pay.
Patient Assistance through Genentech Rheumatology Access Solutions can help your patients obtain the therapy prescribed, regardless of their ability to pay.
Genentech Rheumatology Access Solutions
At Genentech, we develop medicines for serious or life-threatening medical conditions and we believe they should be accessible for the patients who need them.
Our dedicated staff of Specialists can:
- Resolve benefits and coverage issues
- Find co-pay assistance for underinsured patients
- Help uninsured patients apply for free medicine through the Genentech Access to Care Foundation
- Individualize services to meet your patients' specific needs
To speak live with one of our Specialists, call 1-866-681-3261 or visit Genentech Rheumatology Access Solutions.
For shipping information, please contact an authorized specialty distributor:
- Besse Medical/Oncology Supply
- CuraScript Specialty Distribution
- Florida Infusion
- McKesson Specialty Distribution
- Metro Medical Supply
ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
INDICATION
ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
IMPORTANT SAFETY INFORMATION
Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled.
ACTEMRA should not be administered to patients with known hypersensitivity to ACTEMRA.
- If anaphylaxis or other clinically significant hypersensitivity reaction occurs, administration of ACTEMRA should be stopped immediately and ACTEMRA should be permanently discontinued.
Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations and hypersensitivity reactions. Other potential risks of ACTEMRA include demyelinating disorders, malignancies, and changes to certain lab parameters.
Common adverse reactions include upper respiratory infection, nasopharyngitis, headache, hypertension, and increased ALT.
Please see full Prescribing Information including Boxed Warning for additional important safety information.
The resource above is provided in Adobe® Reader® format (PDF). To view or print, you must have Adobe Reader (version 3.0 or higher) installed on your computer. Download the free Adobe Reader here.
